Biocon's partner Mylan gets favourable ruling from US patent authority for 4 devices

"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. This strengthens our resolve to provide a high quality affordable Insulin Glargine to diabetic patients in the US and generate savings for their healthcare system," Biocon Biologics CEO and MD Christiane Hamacher said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2XSqhUQ
via IFTTT